163 related articles for article (PubMed ID: 9231926)
1. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma.
Tsai JF; Chuang LY; Jeng JE; Yang ML; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Medicine (Baltimore); 1997 May; 76(3):213-26. PubMed ID: 9193456
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
5. Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Scand J Gastroenterol; 1997 Mar; 32(3):254-60. PubMed ID: 9085463
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
Ali MA; Koura BA; el-Mashad N; Zaghloul MH
Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Scand J Gastroenterol; 2005 Jan; 40(1):68-75. PubMed ID: 15841717
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
9. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Yeh YC; Tsai JF; Chuang LY; Yeh HW; Tsai JH; Florine DL; Tam JP
Cancer Res; 1987 Feb; 47(3):896-901. PubMed ID: 2433030
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma.
Song BC; Chung YH; Kim JA; Choi WB; Suh DD; Pyo SI; Shin JW; Lee HC; Lee YS; Suh DJ
Cancer; 2002 Jan; 94(1):175-80. PubMed ID: 11815974
[TBL] [Abstract][Full Text] [Related]
11. Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Tsai JH
Hepatology; 1997 May; 25(5):1141-6. PubMed ID: 9141431
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
13. Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
Lin GH; Wang J; Li SH; Wang J; Xu L; Li SP
Chin J Cancer; 2010 Apr; 29(4):403-7. PubMed ID: 20346216
[TBL] [Abstract][Full Text] [Related]
14. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis.
Tomiya T; Fujiwara K
Cancer; 1996 Mar; 77(6):1056-60. PubMed ID: 8635123
[TBL] [Abstract][Full Text] [Related]
15. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study.
Chaminda SR; Suchintha T; Anuk NM; Supun DA; Bhagya GM; Habarakada LCA; Janaka SH
BMC Gastroenterol; 2017 Dec; 17(1):142. PubMed ID: 29207969
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients.
Burnett NP; Dunki-Jacobs EM; Callender GG; Anderson RJ; Scoggins CR; McMasters KM; Martin RC
Am Surg; 2013 Jul; 79(7):716-22. PubMed ID: 23816006
[TBL] [Abstract][Full Text] [Related]
18. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
19. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use.
Giannini EG; Sammito G; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Gasbarrini A; Sacco R; Foschi FG; Missale G; Morisco F; Svegliati Baroni G; Virdone R; Trevisani F;
Cancer; 2014 Jul; 120(14):2150-7. PubMed ID: 24723129
[TBL] [Abstract][Full Text] [Related]
20. Increased Serum Endoglin and Transforming Growth Factor β1 mRNA Expression and Risk of Hepatocellular Carcinoma in Cirrhotic Egyptian Patients.
Teama S; Fawzy A; Teama S; Helal A; Drwish AD; Elbaz T; Desouky E
Asian Pac J Cancer Prev; 2016; 17(5):2429-34. PubMed ID: 27268609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
